Jefferies Financial Group Comments on Pieris Pharmaceuticals, Inc.’s Q2 2022 Earnings (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Get Rating) – Analysts at Jefferies Financial Group boosted their Q2 2022 earnings per share (EPS) estimates for Pieris Pharmaceuticals in a note issued to investors on Wednesday, May 11th. Jefferies Financial Group analyst R. Song now expects that the biotechnology company will post earnings per share of ($0.02) for the quarter, up from their prior forecast of ($0.06). Jefferies Financial Group also issued estimates for Pieris Pharmaceuticals’ Q3 2022 earnings at ($0.02) EPS, Q4 2022 earnings at ($0.17) EPS, FY2022 earnings at ($0.16) EPS, FY2023 earnings at ($0.03) EPS, FY2024 earnings at ($0.05) EPS, FY2025 earnings at ($0.08) EPS and FY2026 earnings at ($0.13) EPS.

Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.05. Pieris Pharmaceuticals had a negative return on equity of 93.41% and a negative net margin of 175.99%. During the same quarter in the prior year, the company earned ($0.07) earnings per share.

Separately, StockNews.com assumed coverage on Pieris Pharmaceuticals in a research report on Thursday, March 31st. They issued a “hold” rating on the stock.

Shares of Pieris Pharmaceuticals stock opened at $1.71 on Monday. The stock has a fifty day simple moving average of $2.92 and a 200 day simple moving average of $3.32. Pieris Pharmaceuticals has a 12-month low of $1.61 and a 12-month high of $6.15. The company has a market capitalization of $126.71 million, a P/E ratio of -2.48 and a beta of 1.19.

A number of hedge funds have recently bought and sold shares of the business. Oppenheimer & Co. Inc. purchased a new position in shares of Pieris Pharmaceuticals during the 1st quarter valued at $32,000. XTX Topco Ltd purchased a new position in shares of Pieris Pharmaceuticals during the 1st quarter valued at $46,000. Royal Bank of Canada lifted its position in shares of Pieris Pharmaceuticals by 226.0% during the 2nd quarter. Royal Bank of Canada now owns 12,975 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 8,995 shares during the last quarter. Cetera Advisors LLC purchased a new position in shares of Pieris Pharmaceuticals during the 3rd quarter valued at $52,000. Finally, Bailard Inc. purchased a new position in shares of Pieris Pharmaceuticals during the 1st quarter valued at $59,000. 65.30% of the stock is currently owned by institutional investors and hedge funds.

About Pieris Pharmaceuticals (Get Rating)

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids.

Recommended Stories